Immune Cell Therapy for Advanced Solid Tumors

Immune Cell Therapy for Advanced Solid Tumors is a phase 1/2, interventional study registered as NCT07260058 by Liaoning Medical Diagnosis and Treatment Technology Research and Development Co., Ltd., with a registry enrolment figure of 48 participants, started 2025-12-01 and due to reach its primary completion in 2027-06-30. Interventions recorded: Autologous immune Cells; Standard chemotherapy. Conditions listed: Lung Cancer (Locally Advanced or Metastatic); Liver Cancer (Locally Advanced or Metastatic); Colorectal Cancer (Locally Advanced or Metastatic); Breast Cancer (Locally Advanced or Metastatic); Advanced Solid Tumors. Primary outcome: Phase II Primary Outcome: Objective Response Rate (ORR); Phase I Primary Outcome: Incidence of Adverse Events (AEs). Colorectal eligibility wording from the registry: "Histologically and/or cytologically confirmed locally advanced or metastatic solid tumor: lung cancer, liver cancer, colorectal cancer, or breast cancer". No results are recorded here; the registry entry is the source.